Lumping all inflammatory bowel disease into a single surgical risk category may be masking a clinically important distinction — one that affects how orthopedic surgeons counsel and manage patients heading into joint replacement surgery. A large database analysis now demonstrates that Crohn's disease and ulcerative colitis carry meaningfully different infection profiles after arthroplasty, a finding with direct implications for preoperative risk stratification.
Drawing on an all-payer claims database covering 2016–2023, investigators identified over 10,000 IBD patients who underwent primary elective total joint arthroplasty and matched them to more than 70,000 controls using propensity score matching that adjusted for age, sex, and comorbidity burden. When IBD was treated as a single entity, 90-day periprosthetic joint infection rates did not differ significantly from controls (0.71% vs. 0.61%). However, disaggregating by diagnosis revealed a clear divergence: Crohn's disease patients carried a 0.86% infection rate versus 0.62% in matched controls, translating to an adjusted odds ratio of 1.38 (95% CI: 1.01–1.89) after multivariable regression. Ulcerative colitis patients, by contrast, showed no statistically significant elevation in risk (0.53% vs. 0.64%).
This divergence likely reflects biologically distinct disease mechanisms rather than simply differing disease burdens. Crohn's disease involves transmural, granulomatous inflammation affecting the entire gastrointestinal tract and is more commonly treated with immunosuppressive biologics — agents known to blunt the immune response to surgical pathogens. Ulcerative colitis, confined to the colonic mucosa, may confer a less systemic immunological disruption. The study's observational design using administrative claims data limits causal inference and cannot fully capture medication status, disease activity, or nutritional deficits at time of surgery — all factors plausibly mediating infection susceptibility. The cohort size, however, is among the largest to address this question, lending statistical credibility. Clinically, this finding is incremental but practically useful: it supports treating Crohn's disease — not IBD broadly — as a discrete risk flag in preoperative joint replacement planning.